SilverHut's February 23rd trading volume was $389 million, ranking 320th among U.S. stocks on that day.

K-LinePoet · 2026-02-24T09:09:42+00:00

Silvertech (PODD) had a trading volume of $389 million on February 23, 2026, a 15.66% increase from the previous day, and the stock price rose by 3.10% to $249.38. The company focuses on developing insulin delivery systems, and its products have received FDA approval.

K-LinePoet

2026-02-24 09:09:42

Abstract generation in progress

On February 23, 2026, Insulet Corporation (PODD) had a trading volume of $389 million, ranking 320th among U.S. stocks that day, with a 15.66% increase from the previous day. The trading volume was 1.5675 million shares.

On February 23, 2026, PODD rose 3.10%, closing at $249.38. The stock increased by 2.74% over the past five trading days, declined by 2.51% for the entire February, has fallen 12.26% since the beginning of the year, and decreased by 11.82% over the past 52 weeks.

*If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to now (this also applies if listed for less than 1 month or fewer than 5 trading days).

Insulet (PODD)	Trading Volume / USD	Change from Previous Day	Shares Traded
February 23, 2026	$389 million	+15.66%	1.5675 million
February 20, 2026	$337 million	-3.86%	1.3962 million
February 19, 2026	$350 million	-35.62%	1.4164 million
February 18, 2026	$544 million	+79.50%	2.0738 million
February 17, 2026	$303 million	+59.41%	1.2291 million

Insulet Corporation, founded in 2000 in Delaware, primarily develops, manufactures, and sells its proprietary insulin delivery systems for insulin-dependent diabetics. The Omnipod platform includes: Omnipod 5 automated insulin delivery system, Omnipod DASH insulin management system, Omnipod insulin management system, and the latest innovative product Omnipod G™. In 2023, it received approval from the U.S. Food and Drug Administration. The company also produces Pods for Amgen, used in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta that helps reduce infection risks after intensive chemotherapy.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.